CBD for Gastroparesis: The One Trial That Exists and Why the Guidelines Say No

You order the small portion because the big one is going to sit there. Twenty minutes later you feel sick, and the food you barely ate is still there. If that is your week, you may have been told the word gastroparesis, the clinical name for a stomach that empties food slowly, and that nothing much helps.

Then a friend mentions cannabis, and you wonder whether a cannabis extract could help.

The honest answer is more complicated than either the hype or the dismissal. There is exactly one randomised controlled trial of prescription cannabidiol in gastroparesis. It was small, short, and published in a respectable gastrointestinal journal. Its authors concluded that CBD provides symptom relief despite slowing of gastric emptying. Two years later, the American Gastroenterological Association issued a clinical practice guideline with a conditional recommendation against cannabidiol as first-line therapy. Both are true at once, and if you read only one, you are being misled.

What Gastroparesis Actually Is

Gastroparesis means the stomach muscles move food out more slowly than normal without a physical blockage. Symptoms typically include feeling full after a few bites, nausea, bloating, upper abdominal pain and sometimes vomiting. Food that lingers also distorts blood sugar, which is why many people with the condition are tested for diabetes. Causes are mixed. Many are idiopathic, meaning no clear cause was found. Others follow diabetes, surgery affecting stomach nerves, or illness.

Two things follow. First, gastroparesis is diagnosed with a test, not a symptom list, and that test has been changing. Second, a treatment that reduces how full you feel is not automatically a treatment that improves how your stomach works, and those two outcomes can move in opposite directions.

The One Randomised Trial Behind the Hype

The anchor evidence is a randomised, double-blinded, placebo-controlled trial published in Clinical Gastroenterology and Hepatology in December 2023, registered as NCT03941288. It enrolled 44 patients, 32 with idiopathic gastroparesis, 6 with type 1 diabetes and 6 with type 2 diabetes. Participants received prescription Epidiolex, the branded pharmaceutical CBD oral solution, titrated twice daily up to a target of 20 mg/kg per day, or a placebo, for four weeks.

The design is the strong part. Randomised, double-blinded and placebo-controlled means neither participants nor trial staff knew who was getting CBD, the best way to rule out expectation bias.

The weaknesses are size and length. Forty-four people is a small trial. Four weeks is short. Small trials can produce large effects that later shrink, and short trials cannot tell you whether benefit holds. There is no long-term safety data.

The accurate description is not that CBD has been shown to work for gastroparesis. It is that a single small, well-conducted, four-week trial found symptomatic benefit, and the specialist guideline read that evidence and still declined to put it first.

What the Trial Measured and What It Found

The trial used the Gastroparesis Cardinal Symptom Index, the main validated scoring tool for this condition, so the result can be compared with other gastroparesis studies. Reported findings from the 2023 Clinical Gastroenterology and Hepatology trial:

• Total Gastroparesis Cardinal Symptom Index score improved on CBD versus placebo, reported P = .008
• Inability to finish a normal-sized meal decreased, reported P = .029
• Vomiting episodes per 24 hours fell, reported P = .006
• Overall symptom severity was reduced, reported P = .034
• Volume to comfortable fullness and maximum tolerance were both higher on CBD, meaning participants could eat more before feeling full

These are four separate symptom measurements pointing the same direction, in a blinded trial. That is meaningful signal, and it is why the study matters.

Now read that list again, because this is where most summaries get it wrong. The outcome that improved was the symptom score. The trial did not establish that CBD corrects the motility problem, improves emptying of solids, changes gut nerve signalling, or prevents long-term complications such as malnutrition. If a product page says CBD treats gastroparesis, ask which outcome it means.

The Twist: Symptoms Improved While the Stomach Slowed Down

This is the detail worth a minute, because it is the part that is easy to leave out of a summary.

In the same trial, gastric emptying was slower on CBD than on placebo. The authors' own conclusion states that CBD provides symptom relief and improves tolerance of liquid nutrient intake despite slowing of gastric emptying. That slowdown was not a footnote. It was part of the result.

There are plausible ways to reconcile this. The 2023 Gut paper from the Rome Foundation and the European Society for Neurogastroenterology and Motility notes that the solid-meal test and the symptom experience do not always track each other cleanly. Liquids and solids empty by different mechanisms, and symptoms can reflect how the small bowel and nervous system respond to food arriving, not only the stomach.

But the honest position is that this is an unresolved tension, not a solved one. The trial shows people felt better while the test showed their stomachs emptying more slowly. It does not show why, whether the pattern persists, or whether slower emptying carries clinical risk in people already malnourished.

If your gastroparesis is severe enough that you have lost weight, struggle to hydrate, or have needed a feeding tube, that gap deserves a conversation with your specialist.

The Side Effects Nobody Talks About

The trial reported these most common adverse events among the CBD group:

• Diarrhoea: 14 patients
• Fatigue: 8 patients
• Headache: 8 patients
• Nausea: 7 patients

Five patients could not tolerate the full dose escalation, three withdrew, and 95 percent completed the four weeks. Those numbers are not catastrophic, but they deserve a plain reading. In a condition where nausea and reduced intake are the main problem, seven participants reporting nausea as an adverse event is not trivial. And where a third reported diarrhoea, the effect sizes need context.

Two further points about the product. The trial used prescription Epidiolex, a purified pharmaceutical CBD oral solution. That is not a gummy, a chocolate bar, or a tincture dropped under the tongue. Dosing was weight-based at up to 20 mg per kilogram per day, escalated under supervision. A consumer product does not arrive pre-set at that dose, and the result may not transfer to another format.

The 2025 review in European Archives of Psychiatry and Clinical Neuroscience on cannabis, cannabinoids, health, risks and medical benefits, and the 2023 BMJ umbrella review of meta-analyses, both point to common side effects and drug interactions on top of any condition benefit.

What the American Gastroenterological Association Says

In October 2025, Gastroenterology published the "AGA Clinical Practice Guideline on Management of Gastroparesis," developed using the GRADE framework with 12 recommendations. The one that matters here is a conditional recommendation against cannabidiol as a first-line therapy for gastroparesis.

Conditional rather than strong means the panel believes the balance of benefits and harms is close, and that reasonable clinicians might differ for individual patients. It does not mean CBD is proven useless. It does mean the specialty body for gastroenterology, reviewing the best available evidence, did not put CBD first, for exactly the reason this post describes: the evidence is one 44-patient, four-week trial.

The same guideline recommended against two-hour gastric emptying testing in favour of four-hour testing, and issued conditional recommendations for metoclopramide and erythromycin. It also recommended against domperidone, prucalopride, aprepitant, nortriptyline and buspirone as first-line options.

Read that list as a whole and the message is clear. The panel did not identify CBD as uniquely effective. It evaluated it alongside drugs that also did not earn first-line status. For a condition where food intake and hydration are limiting, it wanted better evidence and safer options.

How Stomach Emptying Is Actually Measured

The 2023 Gut paper on optimal measurement of gastric emptying of solids set out the standardised protocols the field uses. The core method is a standardised solid meal with a small marker, tracked over four hours with a nuclear medicine scan, reporting the percentage emptied. Less than 60 percent emptied at four hours supports the gastroparesis diagnosis.

The AGA recommendation to move away from two-hour testing exists because two-hour testing produces a meaningful number of false negatives, labelling people with delayed emptying who actually have normal emptying. Two consequences follow. If your diagnosis came from a two-hour test, ask whether it would be repeated with the longer protocol. And if you read a study claiming a treatment sped up emptying, check which protocol it used.

The Gut Biology, and Why a Lab Dish Is Not a Patient

The 2023 review in Clinical Gastroenterology and Hepatology on cannabinoids and the gastrointestinal tract outlines the endocannabinoid system in the gut, including cannabinoid receptors on gut tissue and the way the body makes its own cannabinoids. It is a review of mechanism, which justifies a human trial without proving anything.

A 2024 study in Membranes (Basel) looked at whether CBD strengthens gastric tight junction complexes. This was lab work, not a human study. Human claudin-4, claudin-5 and claudin-18.2 proteins were expressed in Xenopus oocytes, exposed to CBD at 20 or 40 micromolar, and junction contact area and strength were measured after 24 hours. It is a dish experiment. Xenopus oocytes are eggs from a frog, with no stomach, no nervous system, no patient and no symptom in that model. A plausible barrier mechanism is worth building on, but nothing about tight junction strength in oocytes tells you that anyone with gastroparesis feels better.

What the Broader Cannabis Reviews Conclude

The 2026 JAMA review on the therapeutic use of cannabis and cannabinoids is a recent, high-quality synthesis of the clinical evidence base. The 2026 Annals of Internal Medicine updated systematic review of cannabis-based products for chronic pain is a large synthesis on tolerability and interactions. The 2023 BMJ umbrella review of meta-analyses looks for consistent signals.

The consistent messages matter. Cannabinoid products are not interchangeable, so a result for one preparation says little about another. Side effects are common. Interactions with other medicines matter for anyone taking several drugs, which is common in gastroparesis. And where results exist for other conditions, effect sizes tend to be small.

If you take prescription medicines, CBD may matter to your pharmacist or doctor for interaction reasons rather than for the gastroparesis itself. Our CBD and drug interactions guide covers that, and our CBD safety guide covers tolerability.

One point if your work involves driving or machinery. The broader reviews flag impairment and sedation as recurring concerns, and the fatigue signal in the trial deserves taking seriously there. Our CBD drug test guide is relevant in regulated workplaces.

How to Spot an Oversold Claim

When you read a product page or an AI-generated summary, these are the tells:

• It promises a cure. No cannabis-based product has been shown to reverse gastroparesis.
• It cites a 44-person study as proof. That trial is a starting point, not proof, and it is the entire evidence base.
• It skips the guideline. If a piece about CBD for gastroparesis does not mention the 2025 AGA conditional recommendation, that omission is the story.
• It quotes a percentage with no source. The only percentages in the trial are the 95 percent completion rate and the P values.
• It confuses symptom relief with emptying improvement. These moved in opposite directions in the one blinded trial.
• It treats a cell study as a human result. The tight junction work is oocytes in a dish.
• It ignores the side effect list. Diarrhoea in 14 of 44 participants, and nausea in 7 of 44, in a condition whose main complaint is nausea.

Our CBD dosage guide explains how dosing is reasoned about, and the CBD and doctor conversation guide is worth reading beforehand.

What You Can Actually Do

If gastroparesis is affecting your life, the useful steps come before any supplement decision.

• Get the diagnosis right. Confirm whether you had a four-hour gastric emptying study and keep the result. If it was a two-hour test, ask whether the longer protocol is worth repeating.

• Ask about the guideline, by name. Tell your specialist you have read the 2025 AGA guideline in Gastroenterology and ask how they read the conditional recommendation against cannabidiol as first-line.

• Bring the trial, not the internet. Hand your specialist the 2023 Clinical Gastroenterology and Hepatology trial and ask about the slower emptying on CBD.

• List everything you take. Prescription medicines, over-the-counter products, supplements. A pharmacist belongs in that conversation.

• Track symptoms before you change anything. A daily log of symptoms, meal size and weight gives you a baseline, so anything you trial after becomes a clean comparison.

• Set a review date in advance. If you and your doctor agree to try CBD as an addition, decide how long you will trial it and what would make you stop. Four weeks, a target symptom, a weight check and a review date is reasonable.

• Do not change prescribed therapy because of an article. Nothing in the evidence supports replacing medical care with a supplement.

Bottom Line

There is one small randomised trial showing CBD reduced gastroparesis symptoms over four weeks in 44 people, and the American Gastroenterological Association conditionally recommends against it as first-line therapy. Both are true. In that trial, symptoms improved while gastric emptying slowed, and a third of participants reported diarrhoea.

So is CBD worth asking about? It is worth asking about, and it is not worth assuming. This is not a treatment with a body of evidence behind it. It is one study, and a careful professional body looked at it and did not put it first.

Bring specific questions to your doctor: is my diagnosis confirmed on a four-hour study, how do you read the AGA recommendation, what would a monitored trial look like for me, and what should I watch for. Then let their answer decide.